Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 61

1.

Blood pressure control by drug group in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Cushman WC, Ford CE, Einhorn PT, Wright JT Jr, Preston RA, Davis BR, Basile JN, Whelton PK, Weiss RJ, Bastien A, Courtney DL, Hamilton BP, Kirchner K, Louis GT, Retta TM, Vidt DG; ALLHAT Collaborative Research Group.

J Clin Hypertens (Greenwich). 2008 Oct;10(10):751-60. doi: 10.1111/j.1751-7176.2008.00015.x.

2.

Heart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack trial.

Davis BR, Kostis JB, Simpson LM, Black HR, Cushman WC, Einhorn PT, Farber MA, Ford CE, Levy D, Massie BM, Nawaz S; ALLHAT Collaborative Research Group.

Circulation. 2008 Nov 25;118(22):2259-67. doi: 10.1161/CIRCULATIONAHA.107.762229. Epub 2008 Nov 10.

3.

Risk/benefit assessment of beta-blockers and diuretics precludes their use for first-line therapy in hypertension.

Messerli FH, Bangalore S, Julius S.

Circulation. 2008 May 20;117(20):2706-15; discussion 2715. doi: 10.1161/CIRCULATIONAHA.107.695007. No abstract available.

4.

Thiazide-type diuretics and beta-adrenergic blockers as first-line drug treatments for hypertension.

Cutler JA, Davis BR.

Circulation. 2008 May 20;117(20):2691-704; discussion 2705. doi: 10.1161/CIRCULATIONAHA.107.709931. Review. No abstract available.

5.

Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Wright JT Jr, Harris-Haywood S, Pressel S, Barzilay J, Baimbridge C, Bareis CJ, Basile JN, Black HR, Dart R, Gupta AK, Hamilton BP, Einhorn PT, Haywood LJ, Jafri SZ, Louis GT, Whelton PK, Scott CL, Simmons DL, Stanford C, Davis BR.

Arch Intern Med. 2008 Jan 28;168(2):207-17. doi: 10.1001/archinternmed.2007.66.

6.

Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Black HR, Davis B, Barzilay J, Nwachuku C, Baimbridge C, Marginean H, Wright JT Jr, Basile J, Wong ND, Whelton P, Dart RA, Thadani U; Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.

Diabetes Care. 2008 Feb;31(2):353-60. Epub 2007 Nov 13.

PMID:
18000186
7.

Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system.

Blood Pressure Lowering Treatment Trialists' Collaboration, Turnbull F, Neal B, Pfeffer M, Kostis J, Algert C, Woodward M, Chalmers J, Zanchetti A, MacMahon S.

J Hypertens. 2007 May;25(5):951-8. Erratum in: J Hypertens. 2007 Jul;25(7):1524.

PMID:
17414657
8.

The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Heart Failure Validation Study: diagnosis and prognosis.

Einhorn PT, Davis BR, Massie BM, Cushman WC, Piller LB, Simpson LM, Levy D, Nwachuku CE, Black HR; ALLHAT Collaborative Research Group.

Am Heart J. 2007 Jan;153(1):42-53.

PMID:
17174636
9.

Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Barzilay JI, Davis BR, Cutler JA, Pressel SL, Whelton PK, Basile J, Margolis KL, Ong ST, Sadler LS, Summerson J; ALLHAT Collaborative Research Group.

Arch Intern Med. 2006 Nov 13;166(20):2191-201.

PMID:
17101936
10.

Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial.

Leenen FH, Nwachuku CE, Black HR, Cushman WC, Davis BR, Simpson LM, Alderman MH, Atlas SA, Basile JN, Cuyjet AB, Dart R, Felicetta JV, Grimm RH, Haywood LJ, Jafri SZ, Proschan MA, Thadani U, Whelton PK, Wright JT; Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group.

Hypertension. 2006 Sep;48(3):374-84. Epub 2006 Jul 24.

11.

Thiazide-associated glucose abnormalities: prognosis, etiology, and prevention: is potassium balance the key?

Cutler JA.

Hypertension. 2006 Aug;48(2):198-200. Epub 2006 Jun 26. No abstract available.

12.

Preventing cardiovascular disease and diabetes: a call to action from the American Diabetes Association and the American Heart Association.

Eckel RH, Kahn R, Robertson RM, Rizza RA.

Circulation. 2006 Jun 27;113(25):2943-6. No abstract available.

13.

Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.

Davis BR, Piller LB, Cutler JA, Furberg C, Dunn K, Franklin S, Goff D, Leenen F, Mohiuddin S, Papademetriou V, Proschan M, Ellsworth A, Golden J, Colon P, Crow R; Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group.

Circulation. 2006 May 9;113(18):2201-10. Epub 2006 May 1.

14.

Executive summary: HFSA 2006 Comprehensive Heart Failure Practice Guideline.

Heart Failure Society Of America.

J Card Fail. 2006 Feb;12(1):10-38. Review.

PMID:
16500578
15.

Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure.

Ernst ME, Carter BL, Goerdt CJ, Steffensmeier JJ, Phillips BB, Zimmerman MB, Bergus GR.

Hypertension. 2006 Mar;47(3):352-8. Epub 2006 Jan 23.

16.

Pathophysiologic, diagnostic, and therapeutic aspects of the metabolic syndrome.

Giles TD, Sander GE.

J Clin Hypertens (Greenwich). 2005 Nov;7(11):669-78. Review.

17.

ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society.

Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW, Antman EM, Smith SC Jr, Adams CD, Anderson JL, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; American College of Chest Physicians; International Society for Heart and Lung Transplantation; Heart Rhythm Society.

Circulation. 2005 Sep 20;112(12):e154-235. Epub 2005 Sep 13. No abstract available.

18.

Blood pressure reduction and cardiovascular prevention: an update including the 2003-2004 secondary prevention trials.

Staessen JA, Li Y, Thijs L, Wang JG.

Hypertens Res. 2005 May;28(5):385-407. Review.

PMID:
16156503
19.

Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA).

Poulter NR, Wedel H, Dahlöf B, Sever PS, Beevers DG, Caulfield M, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J, Pocock S; ASCOT Investigators.

Lancet. 2005 Sep 10-16;366(9489):907-13.

PMID:
16154017
20.

Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial.

Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J; ASCOT Investigators.

Lancet. 2005 Sep 10-16;366(9489):895-906.

PMID:
16154016

Supplemental Content

Support Center